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The development of multiple sclerosis is the 
result of complex interactions between environmental 
factors, genetic factors that determine individual disease 
susceptibility, and immunological and physiological 
characteristics of the patient [1, 2]. Multiple sclerosis 
treatment requires obtaining information about the main 
pathological processes, therefore, the evaluation of 
biochemical, immunological, and genetic markers of 
such processes, and not just clinical indicators, can 
become the basis of improved approaches for diagnosis 
and monitoring of the disease [3-6]. Polymorphism of the 
disease-associated genes is considered as one of the key 
factors in multiple sclerosis pathogenesis, capable of 
influencing the risk of development, clinical 
manifestations and nature of the course of the disease, 
treatment response [7]. The HLA genes polymorphism 
was found to be the most important and playing an 
essential role in the development of autoimmune 
diseases. For example, the presence of the polymorphic 
version of HLA-DRB1*15:01 gives a threefold increase 
in the risk of multiple sclerosis, and in the case of 
monozigency, the disease susceptibility increases by 6-7 
times [7-9]. There are data on the population 
characteristics of these types of polymorphisms, which 
require conducting relevant research in Ukraine and its 
regions to identify relevant genetic markers [9, 10]. The 
aim of the study was to provide a comparative clinical 
and immunological characteristic of multiple sclerosis 
patients in the northeastern region of Ukraine, depending 
on the presence of the disease-associated HLA-DR 
polymorphism. 
 
Materials and methods 
39 patients with multiple sclerosis, inhabitants 
of Kharkiv and Kharkiv region, were examined, of which 
7 men and 32 women of medium age of 33.7 ± 7.7 and 
42.1 ± 11.9 years, respectively; control group was 
consisted of 27 practically healthy persons of both sexes 
with an average age of 30.1 ± 8.2 years. Patients were on 
outpatient and inpatient treatment at the Institute of 
Neurology, Psychiatry and Narcology of the National 
Academy of Medical Sciences of Ukraine, the study was 
carried out on the basis of the Laboratory of Clinical 
Immunology and Allergology, Mechnikov Institute of 
Microbiology and Immunology of the National Academy 
of Medical Sciences of Ukraine. The inclusion criteria 
were 1) the presence of a verified diagnosis of multiple 
sclerosis (code G35 according to ICD-10), the 
formulation of which was made in accordance with the 
order of the Ministry of Health of Ukraine № 487 dated 
17.08.2007, 2) the lack of disease modifying therapies for 
at least six months before the survey began. All patients 
participated in the study gave voluntary written 
agreement. 
Clinical characteristics of multiple sclerosis 
patients included the determining the form (sporadic or 
familial) and the actual type of the disease, its duration, 
and disability assessment based on the EDSS scale. The 
rate of the disease progression was determined as the 
ratio of the EDSS score to the duration of the disease. 
Biological material was blood and buccal 
epithelium samples from multiple sclerosis patients and 
practically healthy people. In addition to assessing the 
clinical status of the patients, design of the study also 
included evaluation of the systemic immunity indicators, 
levels of nonspecific and antinuclear antibodies in the 
serum, and analysis of HLA polymorphism, in particular, 
detection of the HLA-DRB1*1501-DQB1*0602 (HLA-
DR15) haplotype for its specific marker SNP rs9271366. 
Isolation of high molecular DNA (40.000 – 50.000 bp, 
OD 260/280 nm) was performed on a magnetically 
sensitive sorbent using the NeoPrep100 DNA Magnet kit 
(NeoGene, Ukraine). SNP polymorphism rs9271366 
A/G was typed by the allele-specific amplification 
method with subsequent electrophoretic detection of the 
results. Primer selection was performed using the method 
[11] adding a mismatch in the third position at the 3’ends.  
The primers MS92АF 5`-CACGTAATATAA-
ATGGTTGCAAAGGA-3`, MS92GF 5`-
CACGTAATATAAATGGTTGCA-AAGGG-3` and 
MS92R5` AACCCTGATGTAACAGA(C/T)CTCTA-3` 
(Eurofins Genomics), as well as Taq-mut polymerase 
(Liteh, Russian Federation), were used in the study. The 
amplification was performed on the multichannel 
amplifier Tercyc (Russian Federation). Amplification 
mode: denaturation at 96°C for 3 minutes and 35 cycles 
that included denaturation at 95°C for 30 seconds, 
annealing at 58°C for 30 seconds, and synthesis at 72°C 
for 30 seconds. The length of the amplicon was 233 bp. 
Electrophoresis was performed in 2% agarose gel in TAE 
buffer. Electrophoregram analysis was carried out on 
transilluminator UVT 1 (Biocom, Russian Federation). 
Serum IgM, IgG, IgA levels were evaluated by 
ELISA using a test system by NPL Granum (Ukraine) 
and the immunoassay analyzer Stat-Fax 303 (USA). The 
determination of peripheral blood lymphocytes 
subpopulations was carried out using the test systems 
“Anti-CD3”, “Anti-CD4”, “Anti-CD8”, “Anti-CD16”, 
“Anti-CD22” (NPL Granum, Ukraine). Circulating 
immune complexes (CIC) in serum were evaluated by 
selective precipitation of antigen complexes with 3.5% 
PEG-6000 solution (AppliChem GmbH, Germany). The 
optical density of precipitate was measured 
spectrophotometrically on a Stat-Fax 303 analyzer at 450 
nm. The content of lymphocytotoxic autoantibodies 
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(LCTA) was determined by a lymphocytotoxic 
macrotest. The complementary activity of the blood 
serum was evaluated by means of 50% of sheep 
erythrocytes hemolysis in the presence of homologous 
antibodies. 
The statistical treatment was performed using 
Statistica 11.0 (StatSoft, Inc). To determine the reliability 
of the differences between the indexes in the studied 
samples, the non-parametric Mann-Whitney's criterion 
was used, while the Student's T-criterion was used for the 
normal distribution. 
 
Results and discussion 
At the stage of clinical examination of multiple 
sclerosis patients, 25 patients (64.1%) were diagnosed 
with relapsing-remitting type of multiple sclerosis 
(RRMS), 4 patients (10.3%) with primary progressive 
type (PPMS), and another 10 persons (25,6%) with 
secondary progressive type (SPMS). The familial form of 
the disease was established in 11 cases (28.2%), in 28 
cases (71.8%) the form of the disease was classified as 
sporadic. The average disease duration of the examined 
persons was 10.16 ± 9.57 years. The disability score 
assessed according to the EDSS scale was 3.54 ± 1.67 
points; the rate of progression of the disease was 0.93 ± 
1.26 and 0.83 ± 0.85 points, respectively. 
The next stage of the study was to establish the 
presence of the "risk" haplotype HLA-DRB1*1501-
DQB1*0602 in patients by means of the one of its 
specific markers (tag SNP), SNP rs9271366. According 
to [12], the detection of HLA-DRB1*1501 by typing 
SNP rs9271366 has a high sensitivity and specificity of 
more than 97%. The technique we used allowed us to 
clearly differentiate the allele of the given locus. Analysis 
of the HLA polymorphism  indicated that the disease-
associated (minor) allele G SNP rs9271366 was present 
in 43.6% of the subjects examined (heterozygous), and 
another 56.4% of the patients were homozygous by the 
major allele A. According to the presence of alleles A and 
G of SNP rs9271366, multiple sclerosis patients were 
divided into groups G+ (heterozygous, n=17) and G- 
(homozygous for allele A, n=22). All persons in the 
control group were homozygous for the allele A. 
Analysis of the data allowed concluding that the 
form of the disease, disability score and the rate of 
progression in multiple sclerosis patients had no 
association with the SNP rs9271366 minor allele. The 
average EDSS score was 3.45 ± 1.95 points in G+ 
patients and 3.65 ± 1.26 points in G- patients and the rate 
of disease progression was 0.83 ± 0.85 points and 0.93 ± 
1.26 points, respectively. 
The study of cellular immunity indicators (table 
1) revealed a decrease in relative number of CD4+ and 
CD8+ lymphocytes in multiple sclerosis patients 
compared to that in control group, and it was more 
pronounced in subjects with the presence of the SNP 
rs9271366 minor allele. The relative content of CD4 + 
cells was 28.00 ± 3.45% in heterozygous patients, 30.94 
± 4.42% in patients homozygous for allele A, in the 
control group 42.3 ± 1.8% (p<0.05), and the CD8+ cells 
content was 18,55 ± 4.08%, 20.65 ± 3.52% and 29.4 ± 
2.2%, respectively (p<0.05). At the same time, the 
reduction in the relative number of CD4+ lymphocytes 
was observed in 90.9% of G+ patients, and in 64.7% 
cases in G- patients (p<0.05). Decreased CD8+ 
lymphocyte content was also more common in patients 
with G+ (77.3% of cases) than in G- (41.2% of cases), 
p<0.05. 
 
 
Table 1 - Cellular immunity in patients with multiple sclerosis, M±σ 
Indicators Units 
MS patients 
Control group 
Overall G- group G+ group 
Leukocytes cells х109/l 6,5 ± 2,4 6,6 ± 1,9 6,4 ± 2,7 6,7 ± 1,6 
Lymphocytes 
% 29,7 ± 9,9 30,2 ± 7,6 29,4 ± 11,4 28,9 ± 5,7 
cells х109/l 1,8 ± 0,6 2,0 ± 0,6 1,7 ± 0,6 1,9 ± 0,3 
CD3+ 
% 51,7 ± 8,9 53,1 ± 9,0 50,1 ± 7,0 62,7 ± 4,8 
cells х109/l 1,0 ± 0,4 1,1 ± 0,4 0,9 ± 0,3 1,2 ± 0,2 
CD4+ 
% 29,9 ± 4,9* 30,9 ± 4,4* 28,0 ± 3,5* 42,3 ± 1,8 
cells х109/l 0,5 ± 0,2 0,6 ± 0,2 0,5 ± 0,2 0,8 ± 0,2 
CD8+ 
% 19,9 ± 4,4* 20,7 ± 3,5* 18,6 ± 4,1* 29,4 ± 2,2 
cells х109/l 0,4 ± 0,2 0,4 ± 0,2 0,3 ± 0,2 0,6 ± 0,1 
CD16+ 
% 17,9 ± 2,5 18,1 ± 2,2 17,6 ± 2,5 18,5 ± 1,7 
cells х109/l 0,3 ± 0,1 0,3 ± 0,1 0,3 ± 0,1 0,4 ± 0,1 
CD22+ 
% 17,4 ± 3,9 17,1 ± 4,5 18,1 ± 3,2 22,1 ± 2,6 
cells х109/l 0,3 ± 0,1 0,4 ± 0,1 0,3 ± 0,1 0,4 ± 0,1 
__________________ 
* (р < 0,05) compared to the control group. 
 
Acute inflammatory process was determined in 
38.5% of patients with multiple sclerosis, as evidenced 
by an elevated IgM level in 20.5% of cases, as well as an 
increase in complement activity in 62.5% of subjects 
(table 2). The levels of LCTA in patients with multiple 
sclerosis were significantly higher compared to the 
control group (18.33 ± 3.67% of subjects and 5.82 ± 
3.12% of subjects, respectively, p<0.05), and the levels 
of circulating immune complexes were elevated in 10.3% 
of patients who participated in the study. 
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Table 2 - Humoral immunity in patients with multiple sclerosis, M±σ 
Indicators Units 
MS patients 
Control group 
Overall G- group G+ group  
IgA g/l 2,03 ± 0,46 1,94 ± 0,4 2,13 ± 0,49 1,8 ± 0,39 
IgG g/l 12,69 ± 2,43 12,43 ± 1,87 12,98 ± 2,42 10,2 ± 1,12 
IgM g/l 1,46 ± 0,42 1,47 ± 0,44 1,44 ± 0,39 1,15 ± 0,27 
CIC conv. units 77,82 ± 28,22 75,12 ± 19,52 82,0 ± 28,59 84,55 ± 14,1 
LCTA % 17,33 ± 4,58* 18,18 ± 4,42* 18,45 ± 3,07* 5,82 ± 3,12 
Complement 
activity 
hem. units 57,24 ± 12,08 62,06 ± 9,02 54,52 ± 12,83 44,21 ± 7,64 
__________________ 
* (р < 0,05) compared to the control group. 
 
The study of the levels of antinuclear antibodies 
in multiple sclerosis patients revealed a diagnostically 
significant levels of antibodies to native DNA found in 
92.3% of the cases, including all G + patients and 83.3% 
of G- patients (table 3). 
 
Table 3 – Cases of diagnostically significant levels of antinuclear antibodies depending on SNP rs9271366, % 
Indicators 
MS patients 
Control group 
G- group G+ group 
Abs to native DNA 83,3 100 - 
Abs to denaturated DNA 16,7 14,3 - 
Abs to formalinized DNA 16,7 28,6 3,7 
 
In this case, 16.7% of patients homozygous for 
allele A and 14.3% heterozygous patients were also 
positive for the presence of antibodies to denatured DNA. 
Similar results were also obtained concerning the 
presence of antibodies to formalinized DNA - 16.7% 
positive results in G- patients and 28.6% in G+ patients 
(p<0.05). At the same time, elevated levels of antibodies 
to native, denatured, and formalinized DNA were 
determined predominantly in patients with SPMS and 
PPMS (15.4% of the number of examined patients). 
 
Conclusion 
Among the surveyed multiple sclerosis patients, 
inhabitants of Kharkiv and Kharkiv region, the presence 
of the SNP rs9271366 minor allele G was established in 
43.6% (heterozygous, haplotype AG), while 56.4% of the 
patients were homozygous for allele A (haplotype AA). 
The comparative analysis of clinical indicators and 
genetic data of examined patients indicated that the type 
of the disease, EDSS score, and the rate of multiple 
sclerosis progression did not have association with the 
allele G SNP rs9271366. Also, in patients with familial 
and sporadic forms of the disease, there were no 
significant differences in clinical indicators and immune 
status. In patients with multiple sclerosis, the inhibition 
of the cellular immunity was detected, as evidenced by a 
significant decrease in the relative number of CD4+ and 
CD8+ lymphocytes, more pronounced in patients with 
the presence of the SNP rs9271366 minor allele. The 
levels of lymphocytotoxic autoantibodies as well as of 
antinuclear antibodies in patients were significantly 
higher than that in the control group. Antibodies to native 
DNA were detected in 92.3% of patients. At the same 
time, the raised levels of antibodies to the native, 
denaturized and formalinized DNA were determined 
predominantly in patients with SPMS and PPMS. The 
elevated levels of antinuclear antibodies may indicate an 
unfavorable course of the disease or its transition to the 
active phase. 
Thus, in the surveyed multiple sclerosis patients 
from the northeastern region of Ukraine, the prevalence 
of SNP rs9271366 and its association with a decrease in 
the relative number of CD4+ and CD8+ cells against the 
background of elevated levels of antinuclear and 
lymphocytotoxic antibodies were detected. 
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DISEASE-ASSOCIATED HLA-DR 
POLYMORPHISM, CLINICAL AND 
IMMUNOLOGICAL CHARACTERISTICS OF 
MULTIPLE SCLEROSIS PATIENTS  
IN THE NORTHEASTERN REGION OF 
UKRAINE 
Kolyada T. І., Negreba T. V., Tupotilov O. V., 
Bilozorov O. P., Zelenska A. D., Kolyada O. M., 
Shvydka O. V., Belyavtseva O. I. 
The development of multiple sclerosis is the result of 
complex interactions between environmental factors, 
genetic factors that determine individual disease 
susceptibility, and immunological and physiological 
characteristics of the patient. multiple sclerosis 
treatment requires obtaining information about the main 
pathological processes, therefore, the evaluation of 
biochemical, immunological, and genetic markers of 
such processes, and not just clinical indicators, can 
become the basis of improved approaches for diagnosis 
and monitoring of the disease. Polymorphism of the 
disease-associated genes is considered as one of the key 
factors in multiple sclerosis pathogenesis, capable of 
influencing the risk of development, clinical 
manifestations and nature of the course of the disease, 
treatment response. The HLA genes polymorphism was 
found to be the most important and playing an essential 
role in the development of autoimmune diseases. There 
are data on the population characteristics of these types 
of polymorphisms, which require conducting relevant 
research in Ukraine and its regions to identify relevant 
genetic markers. The aim of the study was to provide a 
comparative clinical and immunological characteristic 
of multiple sclerosis patients in the northeastern region 
of Ukraine, depending on the presence of the disease-
associated HLA-DR polymorphism. Materials and 
methods. 39 patients with multiple sclerosis, inhabitants 
of Kharkiv and Kharkiv region, were examined, of 
which 7 men and 32 women of medium age of 33.7 ± 
7.7 and 42.1 ± 11.9 years, respectively; control group 
was consisted of 27 practically healthy persons of both 
sexes with an average age of 30.1 ± 8.2 years. Clinical 
characteristics of multiple sclerosis patients included the 
determining the form and the actual type of the disease, 
its duration, and disability assessment based on the 
EDSS scale. The rate of the disease progression was 
determined as the ratio of the EDSS score to the 
duration of the disease. Biological material was blood 
and buccal epithelium samples from multiple sclerosis 
patients and practically healthy people. In addition to 
assessing the clinical status of the patients, design of the 
study also included evaluation of the systemic immunity 
indicators, levels of nonspecific and antinuclear 
antibodies in the serum, and analysis of HLA 
polymorphism, in particular, detection of the HLA-
DR15 haplotype for its specific marker SNP rs9271366. 
Isolation of high molecular DNA was performed on a 
magnetically sensitive sorbent using the NeoPrep100 
DNA Magnet kit (NeoGene, Ukraine). SNP 
polymorphism rs9271366 A/G was typed by the allele-
specific amplification method with subsequent 
electrophoretic detection of the results. Primer selection 
was performed using the method by Liu Jing et al. 
(2012) adding a mismatch in the third position at the 
3’ends.  The primers MS92АF 5`-CACGTAATATAA-
ATGGTTGCAAAGGA-3`, MS92GF 5`-
CACGTAATATAAATGGTTGCA-AAGGG-3` and 
MS92R5` AACCCTGATGTAACAGA(C/T)CTCTA-3` 
(Eurofins Genomics), as well as Taq-mut polymerase 
(Liteh, Russian Federation), were used in the study. The 
amplification was performed on the multichannel 
amplifier Tercyc (Russian Federation). Amplification 
mode: denaturation at 96°C for 3 minutes and 35 cycles 
that included denaturation at 95°C for 30 seconds, 
annealing at 58°C for 30 seconds, and synthesis at 72°C 
for 30 seconds. The length of the amplicon was 233 bp. 
Electrophoresis was performed in 2% agarose gel in 
TAE buffer. Electrophoregram analysis was carried out 
on transilluminator UVT 1 (Biocom, Russian 
Federation). Serum IgM, IgG, IgA levels were evaluated 
by ELISA using a test system by NPL Granum 
(Ukraine) and the immunoassay analyzer Stat-Fax 303 
(USA). The determination of peripheral blood 
lymphocytes subpopulations was carried out using the 
test systems by NPL Granum, Ukraine in accordance 
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with the manufacturer's instructions. Circulating 
immune complexes in serum were evaluated by 
selective precipitation of antigen complexes with 3.5% 
PEG-6000 solution (AppliChem GmbH, Germany). The 
content of lymphocytotoxic autoantibodies was 
determined by a lymphocytotoxic macrotest. The 
complementary activity of the blood serum was 
evaluated by means of 50% of sheep erythrocytes 
hemolysis in the presence of homologous antibodies. 
The statistical treatment was performed using 
STATISTICA 11.0 (StatSoft, Inc). To determine the 
reliability of the differences between the indexes in the 
studied samples, the non-parametric Mann-Whitney's 
criterion was used, while the Student's T-criterion was 
used for the normal distribution. Results. At the stage of 
clinical examination of multiple sclerosis patients, 25 
patients (64.1%) were diagnosed with RRMS, 4 patients 
(10.3%) with PPMS, and another 10 persons (25,6%) 
with SPMS. The familial form of the disease was 
established in 11 cases (28.2%), in 28 cases (71.8%) the 
form of the disease was classified as sporadic. The 
average disease duration of the examined persons was 
10.16 ± 9.57 years. The disability score assessed 
according to the EDSS scale was 3.54 ± 1.67 points; the 
rate of progression of the disease was 0.93 ± 1.26 and 
0.83 ± 0.85 points, respectively. Analysis of the HLA 
polymorphism  indicated that the disease-associated 
(minor) allele G SNP rs9271366 was present in 43.6% 
of the subjects examined (haplotype AG, G+ group), 
and another 56.4% of the patients were homozygous by 
the major allele A (haplotype AA, G- group). The form 
of the disease, the EDSS score, and the rate of the 
disease progression in the examined patients did not 
have association with the allele G SNP rs9271366. 
Patients with familial and sporadic forms of multiple 
sclerosis did not have significant differences in immune 
status and clinical indicators. The average EDSS score 
was 3.45 ± 1.95 points in G+ patients and 3.65 ± 1.26 
points in G- patients and the rate of disease progression 
was 0.83 ± 0.85 points and 0.93 ± 1.26 points, 
respectively. The study of cellular immunity indicators 
revealed a decrease in relative number of CD4+ and 
CD8+ lymphocytes in multiple sclerosis patients 
compared to that in control group, and it was more 
pronounced in subjects with the presence of the SNP 
rs9271366 minor allele. The relative content of CD4 + 
cells was 28.00 ± 3.45% in heterozygous patients, 30.94 
± 4.42% in patients homozygous for allele A, in the 
control group 42.3 ± 1.8% (p<0.05), and the CD8+ cells 
content was 18,55 ± 4.08%, 20.65 ± 3.52% and 29.4 ± 
2.2%, respectively (p<0.05). At the same time, the 
reduction in the relative number of CD4+ lymphocytes 
was observed in 90.9% of G+ patients, and in 64.7% 
cases in G- patients (p<0.05). Decreased CD8+ 
lymphocyte content was also more common in patients 
with G+ (77.3% of cases) than in G- (41.2% of cases), 
p<0.05. Acute inflammatory process was determined in 
38.5% of patients with multiple sclerosis, as evidenced 
by an elevated IgM level in 20.5% of cases, as well as 
an increase in complement activity in 62.5% of subjects. 
The levels of lymphocytotoxic autoantibodies in 
patients with multiple sclerosis were significantly higher 
compared to the control group (18.33 ± 3.67% of 
subjects and 5.82 ± 3.12% of subjects, respectively, 
p<0.05), and the levels of circulating immune 
complexes were elevated in 10.3% of patients. The 
study of the levels of antinuclear antibodies in multiple 
sclerosis patients revealed a diagnostically significant 
levels of antibodies to native DNA found in 92.3% of 
the cases, including all G + patients and 83.3% of G- 
patients. In this case, 16.7% of patients homozygous for 
allele A and 14.3% heterozygous patients were also 
positive for the presence of antibodies to denatured 
DNA. Similar results were also obtained concerning the 
presence of antibodies to formalinized DNA - 16.7% 
positive results in G- patients and 28.6% in G+ patients 
(p<0.05). At the same time, elevated levels of antibodies 
to native, denatured, and formalinized DNA were 
determined predominantly in patients with SPMS and 
PPMS (15.4% of the number of examined patients). The 
elevated levels of antinuclear antibodies may indicate an 
unfavorable course of the disease or its transition to the 
active phase. Conclusion. In the surveyed multiple 
sclerosis patients from the northeastern region of 
Ukraine, the prevalence of SNP rs9271366 and its 
association with a decrease in the relative number of 
CD4+ and CD8+ cells against the background of 
elevated levels of antinuclear and lymphocytotoxic 
antibodies were detected.  
Keywords: multiple sclerosis, disease-associated 
polymorphism of genes, immunopathogenesis. 
 
